Stay updated with breaking news from Michael Pulsipher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON, April 18, 2024 (GLOBE NEWSWIRE) -- In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from vir...
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Bottom Line: In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies